Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.
Yongsheng XieYingcong WangZhijian XuYumeng LuDongliang SongLu GaoDandan YuBo LiGege ChenHui ZhangQilin FengYong ZhangKe HuCheng HuangYu PengXiaosong WuZhiyong MaoJimin ShaoWeiliang ZhuJumei ShiPublished in: Journal of biomedical science (2022)
ClinicalTrials.gov, NCT03670173, Registered 12 September 2018.